drugset / Trial / NCT03769064

Study for Naltrexone on the Abuse Potential of Methylphenidate

NCT03769064

Phase 1 Completed 94 enrolled Avekshan LLC
RandomizedCrossoverTriple-blindTreatment

Summary

The current abuse liability study aims to assess the potential for co-administration of naltrexone (NTX) to reduce the abuse potential of methylphenidate (MPH).

Timeline

Start
2018-03-27
Primary completion
2018-06-20
Completion
2018-06-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 60 mg
Subject Naltrexone Small molecule 50 mg
Subject Naltrexone Small molecule 100 mg

Indications